AU2020344685A1 - Ophthalmic formulations of methotrexate - Google Patents
Ophthalmic formulations of methotrexate Download PDFInfo
- Publication number
- AU2020344685A1 AU2020344685A1 AU2020344685A AU2020344685A AU2020344685A1 AU 2020344685 A1 AU2020344685 A1 AU 2020344685A1 AU 2020344685 A AU2020344685 A AU 2020344685A AU 2020344685 A AU2020344685 A AU 2020344685A AU 2020344685 A1 AU2020344685 A1 AU 2020344685A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- mtx
- sorbitan
- administered
- sio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900060P | 2019-09-13 | 2019-09-13 | |
| US62/900,060 | 2019-09-13 | ||
| US202063044288P | 2020-06-25 | 2020-06-25 | |
| US63/044,288 | 2020-06-25 | ||
| PCT/US2020/050565 WO2021051003A1 (en) | 2019-09-13 | 2020-09-11 | Ophthalmic formulations of methotrexate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020344685A1 true AU2020344685A1 (en) | 2022-04-14 |
Family
ID=74866765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020344685A Abandoned AU2020344685A1 (en) | 2019-09-13 | 2020-09-11 | Ophthalmic formulations of methotrexate |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US12616699B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4028015A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7682512B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220062617A (cg-RX-API-DMAC10.html) |
| CN (1) | CN114423432A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020344685A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3149467A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL291228A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021051003A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021051003A1 (en) | 2019-09-13 | 2021-03-18 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024129979A1 (en) * | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040253243A1 (en) | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US20050101605A1 (en) | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
| WO2005046746A2 (en) | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| MX2007003968A (es) | 2004-10-01 | 2008-03-04 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
| CA2597590A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations for ocular treatment |
| JP2008539276A (ja) | 2005-04-27 | 2008-11-13 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法 |
| US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| US20110200662A1 (en) | 2008-10-22 | 2011-08-18 | Arnold Glazier | Method For The Treatment Of Proliferative Disorders Of The Eye |
| CN105362221A (zh) | 2009-03-03 | 2016-03-02 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| GB201200192D0 (en) * | 2012-01-06 | 2012-02-22 | Rosemont Pharmaceuticals Ltd | Methotrexate composition |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| US20140105956A1 (en) | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| CA2991921C (en) | 2014-07-30 | 2023-08-08 | Massachusetts Eye And Ear Infirmary | Methotrexate for proliferative vitreoretinopathy |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| GB201522441D0 (en) * | 2015-12-18 | 2016-02-03 | Midatech Pharma Wales Ltd | Sustained release cyclosporine-loaded microparticles |
| WO2018201146A1 (en) | 2017-04-28 | 2018-11-01 | Case Western Reserve University | Compounds and methods of treating retinal degeneration |
| CA3092828A1 (en) | 2018-03-01 | 2019-09-06 | The Trustees Of Columbia University In The City Of New York | Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress |
| WO2021051003A1 (en) | 2019-09-13 | 2021-03-18 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| US12678440B2 (en) | 2020-02-26 | 2026-07-14 | Case Western Reserve University | Compositions and methods for treating misfolded protein ocular disorders |
| WO2024129979A1 (en) | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
-
2020
- 2020-09-11 WO PCT/US2020/050565 patent/WO2021051003A1/en not_active Ceased
- 2020-09-11 EP EP20863798.3A patent/EP4028015A4/en active Pending
- 2020-09-11 CA CA3149467A patent/CA3149467A1/en active Pending
- 2020-09-11 US US17/753,721 patent/US12616699B2/en active Active
- 2020-09-11 KR KR1020227012402A patent/KR20220062617A/ko not_active Ceased
- 2020-09-11 JP JP2022515885A patent/JP7682512B2/ja active Active
- 2020-09-11 CN CN202080063801.6A patent/CN114423432A/zh active Pending
- 2020-09-11 AU AU2020344685A patent/AU2020344685A1/en not_active Abandoned
-
2022
- 2022-03-09 IL IL291228A patent/IL291228A/en unknown
- 2022-09-15 US US17/932,426 patent/US12005060B2/en active Active
- 2022-09-15 US US17/932,453 patent/US12005061B2/en active Active
-
2026
- 2026-04-09 US US19/643,612 patent/US20260224578A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021051003A1 (en) | 2021-03-18 |
| US20230018197A1 (en) | 2023-01-19 |
| US20230017743A1 (en) | 2023-01-19 |
| US12616699B2 (en) | 2026-05-05 |
| CA3149467A1 (en) | 2021-03-18 |
| KR20220062617A (ko) | 2022-05-17 |
| US12005060B2 (en) | 2024-06-11 |
| US20260224578A1 (en) | 2026-08-06 |
| CN114423432A (zh) | 2022-04-29 |
| EP4028015A4 (en) | 2023-11-15 |
| US20220370460A1 (en) | 2022-11-24 |
| US12005061B2 (en) | 2024-06-11 |
| EP4028015A1 (en) | 2022-07-20 |
| JP7682512B2 (ja) | 2025-05-26 |
| IL291228A (en) | 2022-05-01 |
| JP2022548226A (ja) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12005060B2 (en) | Ophthalmic formulations of methotrexate | |
| US20220184057A1 (en) | Combination treatment of ocular inflammatory disorders and diseases | |
| AU2017200608B2 (en) | Liquid pharmaceutical composition for the treatment of a posterior eye disease | |
| KR20080059280A (ko) | 녹내장의 원발성 및 ２차 형태의 치료 방법 | |
| JP2017531045A (ja) | 眼科用液剤 | |
| JP2021515758A (ja) | ネビボロールを含む医薬組成物 | |
| WO2017066052A1 (en) | Formulations and methods for treating high intraocular pressure | |
| JP2022116147A (ja) | 一酸化窒素放出プロスタミドを含有する眼科用組成物 | |
| JP2017523974A (ja) | 増殖性硝子体網膜症用メトトレキサート | |
| TWI705812B (zh) | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 | |
| US20200206137A1 (en) | Microparticle formulations for delivery of active agents | |
| GR1009419B (el) | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου | |
| US20070043006A1 (en) | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis | |
| JP2007500250A5 (cg-RX-API-DMAC10.html) | ||
| Gaballa et al. | Non‐Steroidal Anti‐Inflammatory Drugs (NSAIDs): Ocular Pharmacology, Pharmaceutical Innovations, and Drug Delivery Perspectives | |
| CN101365456A (zh) | 治疗原发性和继发性形式的青光眼的方法 | |
| ZA200509532B (en) | Formulations or non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |